{"entity":{"id":"paper-joseph-novel-cancer-drugs-budget-impact-sri-lanka-ecancer-2025","kind":"paper","name":"Budget impact of novel cancer drugs in Sri Lanka's state health system","aka":[],"tldr":"Funding every eligible patient with 42 novel cancer drugs in Sri Lanka would cost almost 300 million US dollars a year; restricting them to uses that meet a cost-effectiveness threshold would cost 6 to 13.2 million.","summary":"Published as \"Wisely frugal: ensuring sustainable funding for novel cancer therapeutics through a budget impact analysis in resource-limited settings\". Cancer care in Sri Lanka is mostly provided by the state health system, free at the point of delivery. The authors took median survival gains for each indication of a novel cancer drug from the literature and procurement costs from the Ministry of Health, computed cost per life year gained, and applied thresholds of one and three times GDP per capita (US$3,815 and US$11,445 per life year gained).","asOf":"2026-11-11","links":[{"label":"ecancermedicalscience 2025","url":"https://doi.org/10.3332/ecancer.2025.1941"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/40949479/"}],"tags":[],"related":[],"cancers":["breast-cancer","lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sri-lanka-ministry-of-health"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"ecancermedicalscience","year":2025,"doi":"10.3332/ecancer.2025.1941","pmid":"40949479","authors":"Joseph N, Peiris V, Bamunuarachchi V, et al.","paperType":"methods","findings":["42 novel cancer drugs across 90 indications were analysed.","Only 27 indications met the three times GDP threshold, and 18 drugs met neither threshold for any indication.","Annual cost was US$6 million at the one times GDP threshold and US$13.2 million at three times; without a threshold, treating every eligible patient would cost almost US$300 million a year."],"whatItMeans":"OnCo found no Sri Lankan national health technology assessment body for cancer drugs; this is the kind of analysis that could decide which novel drugs the free state system buys first.","caveats":["Survival gains come from published trials, not Sri Lankan patients.","Thresholds are the authors' choice; OnCo found no official Sri Lankan threshold."]},"route":"/key-papers/paper-joseph-novel-cancer-drugs-budget-impact-sri-lanka-ecancer-2025/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"institution":[{"id":"sri-lanka-ministry-of-health","kind":"institution","name":"Ministry of Health and Mass Media, Sri Lanka","route":"/institutions/sri-lanka-ministry-of-health/"}]}}